[go: up one dir, main page]

WO2007014073A3 - Concentrated protein lyophilates, methods, and uses - Google Patents

Concentrated protein lyophilates, methods, and uses Download PDF

Info

Publication number
WO2007014073A3
WO2007014073A3 PCT/US2006/028476 US2006028476W WO2007014073A3 WO 2007014073 A3 WO2007014073 A3 WO 2007014073A3 US 2006028476 W US2006028476 W US 2006028476W WO 2007014073 A3 WO2007014073 A3 WO 2007014073A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
provides
polymorphs
things
analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/028476
Other languages
French (fr)
Other versions
WO2007014073A2 (en
Inventor
Sampathkumar Krishnan
Monica Pallitto
Samantha Nagle
Shon Lee Crampton
Margaret Speed Ricci
Wenjin Cao
Hong Lin
Yong Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37683844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007014073(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to ES06788180T priority Critical patent/ES2390354T3/en
Priority to AU2006272804A priority patent/AU2006272804B2/en
Priority to US11/996,420 priority patent/US7956160B2/en
Priority to EP06788180A priority patent/EP1912667B1/en
Priority to CA2612937A priority patent/CA2612937C/en
Publication of WO2007014073A2 publication Critical patent/WO2007014073A2/en
Anticipated expiration legal-status Critical
Publication of WO2007014073A3 publication Critical patent/WO2007014073A3/en
Priority to US13/102,733 priority patent/US20120116054A1/en
Priority to AU2011202409A priority patent/AU2011202409A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention provides, among other things, lyophilized compositions of high surface area that comprise a protein and that reconstitute quickly and efficiently to solution of high protein concentration with minimal formation, if any, of foam, effervescence, bubbles, turbidity, or particulates that might be deleterious. The invention also provides, among other things, methods for making the lyophilized compositions. The invention in additional aspects also provides Raman Imaging Spectrographic methods for real time analyses of polymorphs in a sample using PLS algorithms. By way of particular example, the use of the method for the analysis of mannitol polymorphs is described, and the use of the analysis to determine optimum compositions and lyophilization methods for producing lyophilates of pharmaceutical proteins having a predefined distribution of mannitol polymorphs and having the aforementioned reconstitution properties is also described.
PCT/US2006/028476 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses Ceased WO2007014073A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES06788180T ES2390354T3 (en) 2005-07-22 2006-07-20 Lyophilisates of concentrated proteins, procedures and uses
AU2006272804A AU2006272804B2 (en) 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses
US11/996,420 US7956160B2 (en) 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses
EP06788180A EP1912667B1 (en) 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses
CA2612937A CA2612937C (en) 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses
US13/102,733 US20120116054A1 (en) 2005-07-22 2011-05-06 Concentrated protein lyophilates, methods, and uses
AU2011202409A AU2011202409A1 (en) 2005-07-22 2011-05-24 Concentrated protein lyophilates, methods, and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70202505P 2005-07-22 2005-07-22
US60/702,025 2005-07-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/102,733 Division US20120116054A1 (en) 2005-07-22 2011-05-06 Concentrated protein lyophilates, methods, and uses

Publications (2)

Publication Number Publication Date
WO2007014073A2 WO2007014073A2 (en) 2007-02-01
WO2007014073A3 true WO2007014073A3 (en) 2008-10-16

Family

ID=37683844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028476 Ceased WO2007014073A2 (en) 2005-07-22 2006-07-20 Concentrated protein lyophilates, methods, and uses

Country Status (6)

Country Link
US (2) US7956160B2 (en)
EP (2) EP2377554A1 (en)
AU (2) AU2006272804B2 (en)
CA (1) CA2612937C (en)
ES (1) ES2390354T3 (en)
WO (1) WO2007014073A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225652B2 (en) 2012-12-03 2022-01-18 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390354T3 (en) * 2005-07-22 2012-11-12 Amgen, Inc Lyophilisates of concentrated proteins, procedures and uses
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
KR20160091434A (en) * 2007-12-28 2016-08-02 박스알타 인코퍼레이티드 Recombinant vwf formulations
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2009314311B2 (en) 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US9464319B2 (en) 2009-03-24 2016-10-11 California Institute Of Technology Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes
US10196700B2 (en) 2009-03-24 2019-02-05 University Of Chicago Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes
WO2010111265A1 (en) 2009-03-24 2010-09-30 University Of Chicago Slip chip device and methods
US9447461B2 (en) 2009-03-24 2016-09-20 California Institute Of Technology Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US20110131827A1 (en) * 2009-12-09 2011-06-09 Patrick John Ultimate glove dryer
PL2598526T4 (en) 2010-07-29 2019-05-31 Eleven Biotherapeutics Inc AGONISTS AND ANTAGONISTS OF THE TYPE AND CHIMERIC INTERLEUKIN IL-1 RECEPTOR
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING SERIAL HALF LIFE
HUE035774T2 (en) * 2011-08-12 2018-05-28 Merial Inc Vacuum-assisted preservation of biological products, in particular of vaccines
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
WO2013096791A1 (en) * 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
MY164868A (en) * 2012-03-28 2018-01-30 Discovery Lab Inc Lyophilization of synthetic liposomal pulmonary surfactant
WO2013148968A1 (en) * 2012-03-28 2013-10-03 Becton, Dickinson And Company Methods for preparing dry formulations of glucose binding protein
EP2834619A1 (en) * 2012-04-05 2015-02-11 Renishaw Diagnostics Limited A method for calibrating spectroscopy apparatus and equipment for use in the method
RS62509B1 (en) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727584A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Vent gases for use in drying, storing and/or reconstituting biomolecules
DE102012021655B4 (en) * 2012-11-03 2023-03-30 Hof Sonderanlagenbau Gmbh Process for freeze-drying a moist product provided with a solvent
EP2945593A4 (en) * 2013-01-15 2016-08-31 Teva Pharma Lyophilization process
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
TWI828269B (en) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
CN105189559B (en) 2013-03-15 2021-07-13 塔科达有限责任公司 Antibody preparations and their uses
CA2943034C (en) 2014-03-24 2022-06-14 Biogen Ma Inc. Lyophilized factor ix formulations
AU2015280480A1 (en) * 2014-06-26 2017-01-05 Amgen Inc. Protein formulations
TWI745278B (en) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 Reduced foaming vaccine compositions
KR101801566B1 (en) * 2014-12-30 2017-11-28 주식회사 삼양바이오팜 Polymeric nanoparticle lyophilizate and method for preparing the same
CA3099551C (en) 2018-05-10 2025-08-19 Regeneron Pharma FORMULATIONS CONTAINING HIGH-CONCENTRATION VEGF RECEPTOR FUSION PROTEINS
EP3813791A2 (en) 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
US20210187107A1 (en) * 2018-08-29 2021-06-24 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
WO2021158759A2 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product
GB202004010D0 (en) * 2020-03-19 2020-05-06 Res & Innovation Uk Detection of water content in tissue
EP4210679A1 (en) * 2020-09-14 2023-07-19 Amgen Inc. Method of making lyophilized protein formulations
US20240101598A1 (en) * 2020-12-18 2024-03-28 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein
AU2021410709A1 (en) 2020-12-22 2023-05-25 Amgen Inc. Cell culture method
CN113717272B (en) * 2021-08-19 2023-09-05 浙江诸暨聚源生物技术有限公司 Freeze-drying protective agent for improving stability of recombinant human collagen
WO2024172859A1 (en) * 2023-02-17 2024-08-22 Spine Biopharma, Inc. Peptide formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US20020136719A1 (en) * 2000-12-28 2002-09-26 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030026813A1 (en) * 1999-08-24 2003-02-06 Gilad Gallili Vaccine composition and method of using the same
US20040219224A1 (en) * 2001-06-21 2004-11-04 Kirill Yakovlevsky Spherical protein particles and methods for making and using them
US6821515B1 (en) * 1995-07-27 2004-11-23 Genentech, Inc. Protein formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682047D1 (en) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd PROTECTION OF PROTEINS AND SIMILAR.
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6180355B1 (en) 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
CZ300547B6 (en) * 1999-02-22 2009-06-10 University Of Connecticut Novel formulations of factor VIII free of albumin
DE10163459A1 (en) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilized preparation containing antibodies to EGF receptor
DE10211227A1 (en) 2002-03-13 2003-10-02 Aventis Behring Gmbh Process for the reconstitution of lyophilized proteins
CA2554018A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
SV2006002258A (en) * 2004-10-08 2006-09-19 Wyeth Corp IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS
CN101217979A (en) * 2005-06-14 2008-07-09 安姆根有限公司 Self-buffering protein formulations
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
ES2390354T3 (en) * 2005-07-22 2012-11-12 Amgen, Inc Lyophilisates of concentrated proteins, procedures and uses
KR20080071192A (en) * 2005-11-22 2008-08-01 와이어쓰 Immunoglobulin Fusion Protein Formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821515B1 (en) * 1995-07-27 2004-11-23 Genentech, Inc. Protein formulation
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US20030026813A1 (en) * 1999-08-24 2003-02-06 Gilad Gallili Vaccine composition and method of using the same
US20020136719A1 (en) * 2000-12-28 2002-09-26 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them
US20040219224A1 (en) * 2001-06-21 2004-11-04 Kirill Yakovlevsky Spherical protein particles and methods for making and using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ECONOMIDES A.N. ET AL.: "Cytokine traps: multi-component high affinity blockers of cytokine action", NATURE MEDICINE, vol. 9, no. 1, January 2003 (2003-01-01), pages 47 - 52, XP002256034 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225652B2 (en) 2012-12-03 2022-01-18 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
US11993797B2 (en) 2012-12-03 2024-05-28 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof

Also Published As

Publication number Publication date
AU2006272804B2 (en) 2011-02-24
AU2011202409A1 (en) 2011-06-09
EP1912667A4 (en) 2009-05-13
US7956160B2 (en) 2011-06-07
US20080213215A1 (en) 2008-09-04
CA2612937C (en) 2014-05-06
US20120116054A1 (en) 2012-05-10
ES2390354T3 (en) 2012-11-12
EP1912667B1 (en) 2012-08-29
EP2377554A1 (en) 2011-10-19
EP1912667A2 (en) 2008-04-23
AU2006272804A8 (en) 2008-04-17
CA2612937A1 (en) 2007-02-01
AU2006272804A1 (en) 2007-02-01
WO2007014073A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2007014073A3 (en) Concentrated protein lyophilates, methods, and uses
EP2441847A3 (en) Screening methods using syk in combination with tau protein
WO2006012500A3 (en) Crystallization of antibodies or fragments thereof
WO2005063820A3 (en) Il-7 fusion proteins
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
WO2006029078A3 (en) Targeting transducible molecules to specific cell types
ZA201901035B (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
WO2011127001A3 (en) Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials
MXPA05011085A (en) Compositions and methods relating to stop-1.
MY151330A (en) Systems and method for separating proteins from connective tissue
Dauphin Structure and composition of the septal nacreous layer of Nautilus macromphalus L.(Mollusca, Cephalopoda)
WO2007010110A3 (en) Method for detecting aggregate-forming circulating protein forms and agent for capturing formed aggregates
WO2007038524A3 (en) Cocrystallization methods
WO2005085440A8 (en) Method for enriching and/or separating prokaryotic dna using a protein that specifically bonds to unmethylated dna containing cpg-motives
WO2007070604A3 (en) System and method for providing high speed content and services
WO2008015419A3 (en) Protein solubilisation
Hsu et al. Synergistic effect between bacteriophages and nanozymes for hybrid dual recognition of pathogenic bacteria from water, food, and agricultural samples: promising new tools for sensitive and specific biosensing
GB2469395A (en) Methods and compounds for phototransfer
WO2008115887A3 (en) Labeled biomolecular compositions and methods for the production and uses thereof
WO2008126517A1 (en) Novel slc17-type transporter protein in mammal and use thereof
WO2007146268A3 (en) Methods for reducing or preventing liquid-liquid phase separation in high concentration protein salutions
EP2392667A3 (en) Assay for phosphodiesterases
Rukhadze et al. Imitation of artificial membrane system via mobile phases with tween‐80 and cholic acid in biopartitioning micellar chromatography
Ding et al. Expression and Purification of GST-GFMCry 11 B Fusion Protein in E. Coli and Preparation of Polyclonal Antibody Against GFMCry 11 B
EP1771731A4 (en) Detection of truncation mutations by mass spectrometry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2612937

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11996420

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006272804

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006788180

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006272804

Country of ref document: AU

Date of ref document: 20060720

Kind code of ref document: A